Earlier this year, Sharon Laboratories became Sharon Personal Care after expanding its technology base and formulation capabilities with the acquisition of RES Pharma and the cosmetic ingredient and R&D units of B&C. CEO Naama Eylon talks about the Israeli firm’s corporate strategy with editor Tim Probert
Tim Probert (TP): What was the thinking behind the acquisitions of Res Pharma and the B&C units?
Naama Eylon (NE): Sharon Laboratories, as it was, was active for over 25 years in the world of preservation for personal care but it was only in preservatives and anti-microbials. It was who we were and what we did.
We wanted to grow and diversify. In our world of cosmetics, growing by mergers and acquisitions is quite normal. We knew we wanted to acquire companies that do something different than what we did.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.
